Archive
All News
Every briefing, headline, and filing we've published, newest first.
The WeekBriefing
The FDA’s accelerated approval of camizestrant looks bigger than a single product event. It may signal a real …
The WeekSTAT News ↗
Before the end of September, UniQure is expected to report four-year results from the closely tracked clinical…
The WeekBioPharma Dive ↗
Remission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts bel…
The WeekPharmaVoice ↗
The drugmaker hopes to move the needle on challenging cancers and shore up its pipeline as it prepares for the…
The WeekFiercePharma ↗
Shifts in drug pricing and market access policies around the world have caused an "earthquake" that will rever…
The WeekFierceBiotech ↗
Evommune's MRGPRX2 antagonist has flunked another phase 2 trial, wiping out the biotech's last hopes of develo…
The WeekBriefing
Novartis’ del-desiran fell short in a rare muscle disease study, according to BioPharma Dive. The setback reop…
The WeekDrug Channels ↗
By Tyler Novotny We're excited to announce the return of the Drug Channels Leadership Forum (DCLF), taking pla…
The WeekPharmaceutical Technology ↗
The FDA has granted RMAT designation to RiboX Therapeutics' investigational treatment RXRG001 for RIX and hypo…
The WeekSTAT News ↗
"Autonomous AI will likely soon exceed both unaided physicians and physicians aided by AI at five core cogniti…
The WeekBioPharma Dive ↗
Multi-agent AI reasoning at the point of care, with complete data sovereignty built in.…
The WeekPharmaVoice ↗
As betting expands into clinical trial outcomes, drugmakers may need to look beyond employees and scrutinize o…
The WeekFiercePharma ↗
In this week's episode of "The Top Line," we look at the people who kept working the problem, from scientists …
The WeekFierceBiotech ↗
Novo Nordisk has given up on two more phase 3 trials of ziltivekimab, further eroding the prospects for a mole…
The WeekBriefing
Del-desiran failed its phase 3 Harbor primary endpoint, a setback for the asset tied to Novartis’ $12 billion …
The WeekSTAT News ↗
These positive results could open up a new way to treat serious lung disease.…
The WeekPharmaceutical Technology ↗
Osaka is striving to turn world-class life sciences research into a global healthcare industry - testing wheth…
The WeekKFF Health News ↗
At the close of every episode, Chip asks his guests the same question: 'What keeps you up at night?' In this h…
The WeekFiercePharma ↗
Daiichi Sankyo subsidiary American Regent is launching a recall of three lots of generic epinephrine as it bec…
The WeekFierceBiotech ↗
ADARx has reinvigorated its ambitions to go public as the AbbVie-backed biotech looks to fund ongoing clinical…
The WeekBriefing
Mass General Brigham’s Medicare Advantage plan is dropping Dana-Farber, extending an institutional split into …
The WeekPharmaceutical Technology ↗
AtomVie has opened a purpose-built radiopharmaceutical manufacturing facility in Hamilton, Ontario, Canada, wi…
The WeekSTAT News ↗
The American Diabetes Association "continues to move from crisis to crisis to crisis," says one of five member…
The WeekFiercePharma ↗
The Breztri ad prompts viewers to "put a LAMA to work" by depicting an AI-generated llama and his barnyard col…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.